Lys88
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys88  -  TAGLN2 (human)

Site Information
QAstMAFkQMEQIsQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15292958
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 )
Disease tissue studied:
gastric cancer ( 5 ) , lung cancer ( 1 , 2 , 3 ) , non-small cell lung cancer ( 2 , 3 , 6 ) , non-small cell lung adenocarcinoma ( 1 , 2 ) , non-small cell large cell lung carcinoma ( 2 ) , non-small cell squamous cell lung carcinoma ( 1 , 6 ) , ventricular tachycardia ( 7 , 8 )
Relevant cell line - cell type - tissue:
Calu-3 (pulmonary) ( 3 ) , cardiac-heart ( 7 , 8 ) , HCC15 (pulmonary) ( 1 ) , HCC827 (pulmonary) ( 3 ) , HeLa (cervical) ( 4 ) , LOU-NH91 (squamous) ( 1 ) , lung ( 1 , 2 , 3 ) , MKN-45 (gastric) ( 5 ) , NCI-H1299 (pulmonary) ( 2 ) , NCI-H1650 (pulmonary) ( 3 ) , NCI-H1703 (squamous) ( 1 , 6 ) , NCI-H1734 (pulmonary) ( 2 ) , NCI-H1944 (pulmonary) ( 2 ) , NCI-H1975 (pulmonary) ( 3 ) , NCI-H2073 (pulmonary) ( 1 ) , NCI-H2106 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 1 ) , NCI-H358 (pulmonary) ( 2 ) , NCI-H460 (pulmonary) ( 2 )

References 

1

Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790   Curated Info

5

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Li Y (2010) CST Curation Set: 10399; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

8

Li Y (2010) CST Curation Set: 10398; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info